Multiple studies have been performed to evaluate the effects of mesenchymal stem cells (MSCs) in preclinical Parkinson models.
We performed a meta-analysis to estimate the treatment effect of unmodified MSCs on behavioral outcomes in preclinical studies of Parkinson’s disease (PD). We performed a systematic literature search to identify studies that used behavioral testing to evaluate the treatment effect of unmodified MSCs in PD models. Meta-analysis was used to determine pooled effect size for rotational behavior and limb function and meta-regression was performed to explore sources of heterogeneity.
Twenty-five studies including three delivery routes, a wide range of doses, and multiple PD models were examined. Significant improvement was seen in the pooled standardized mean difference (SMD) for both rotational behavior (SMD: 1.24, 95% CI: 0.84,1.64) and limb function (SMD: 0.84, 95% CI: 0.01, 1.66). Using meta-regression, IV administration and higher dose had a larger effect on limb function. Treatment with MSCs improves behavioral outcomes in PD models.
Our analyses suggest that MSCs could be considered for early stage clinical trials in the treatment of PD.
About the article:
Riecke Jenny, Johns Katherine M., Cai Chunyan, Vahidy Farhaan Shaheer, Parsha Kaushik, Furr-Stimming Erin, Schiess Mya, and Savitz Sean I.. Stem Cells and Development. September 15, 2015, 24(18): 2082-2090. doi:10.1089/scd.2015.0127.
About Syncrosome:
Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.